Samsung C&T, KR7028260008

Samsung C&T stock: Q3 operating profit reaches KRW 1.143 trillion

Published on 11/18/2026 at 01:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revenue advanced year over year, while net income declined amid weaker non-operating results. Samsung C&T stock faces mixed earnings signals as construction, trading and bio support growth.

Key earnings developments

  • Samsung C&T's nine-month revenue reached KRW 34.469 trillion, with operating income of KRW 2.895 trillion.
  • Engineering and Construction raised full-year order guidance to KRW 30.1 trillion.
  • Bio and Trading joined Construction as major contributors to segment profit.
Samsung C&T, KR7028260008, Illustration mit AI erstellt.

Samsung C&T reported a mixed third quarter in an earnings summary dated November 16, 2026. Consolidated operating profit reached KRW 1.143 trillion, while net income declined amid weaker non-operating results. The Q3 earnings summary said the figures were consolidated K-IFRS estimates prepared before external auditor review.

Construction lifts outlook

Third-quarter sales rose to KRW 12.008 trillion, an increase of KRW 1.857 trillion from a year earlier. Operating profit increased by KRW 149 billion year over year and KRW 111 billion from the previous quarter, while net profit fell to KRW 801 billion as non-operating losses reached KRW 114 billion.

For the first nine months, revenue totaled KRW 34.469 trillion and operating income reached KRW 2.895 trillion. Net income was KRW 2.802 trillion, and operating cash flow rose to KRW 3.904 trillion from KRW 2.909 trillion in the prior-year period.

Order pipeline gains importance

Engineering and Construction raised its full-year order guidance from KRW 23.5 trillion to KRW 30.1 trillion. The outlook also calls for fourth-quarter sales and operating profit to grow sequentially, while high-tech orders are expected to remain strong in 2027.

Overseas data-center and energy projects are progressing toward construction, giving the division additional exposure to infrastructure investment. Samsung Biologics raised its full-year sales-growth guidance from 15 to 20 percent, while Trading expects weaker fourth-quarter earnings but higher full-year earnings.

Business model and market position

Samsung C&T is headquartered in South Korea and operates four main business groups: Engineering and Construction, Trading and Investment, Fashion, and Resort. Its activities include buildings, infrastructure, plants, housing, renewable-energy projects, industrial-materials trading, fashion brands, theme parks, golf clubs and landscaping. The company also owns Samsung Welstory and holds stakes in Samsung Biologics and Samsung Epis Holdings.

Samsung C&T at a glance

  • Company: Samsung C&T
  • ISIN: KR7028260008
  • Ticker: 028260
  • Primary exchange: Korea Exchange
  • Fiscal year: Calendar year

South Korea's market environment is covered through the KOSPI market overview.

More news and analyses on Samsung C&T stock are available in the company topic.

Disclaimer...
en | KR7028260008 | SAMSUNG C&T | boerse | 70529037 | bgmi